Medical - Healthcare Information Services
Compare Stocks
5 / 10Stock Comparison
PGNY vs CI vs UNH vs ELV vs CVS
Revenue, margins, valuation, and 5-year total return — side by side.
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Healthcare Plans
Medical - Healthcare Plans
PGNY vs CI vs UNH vs ELV vs CVS — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||
|---|---|---|---|---|---|
| Industry | Medical - Healthcare Information Services | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Plans | Medical - Healthcare Plans |
| Market Cap | $1.94B | $75.95B | $344.90B | $82.10B | $115.54B |
| Revenue (TTM) | $1.29B | $277.94B | $449.71B | $200.41B | $407.90B |
| Net Income (TTM) | $68M | $6.29B | $12.04B | $5.24B | $2.93B |
| Gross Margin | 24.1% | 9.3% | 18.8% | 23.2% | 13.9% |
| Operating Margin | 7.5% | 3.4% | 4.2% | 3.8% | 1.5% |
| Forward P/E | 20.0x | 9.5x | 20.7x | 14.1x | 12.4x |
| Total Debt | $24M | $31.46B | $78.39B | $33.23B | $93.59B |
| Cash & Equiv. | $112M | $7.68B | $24.36B | $9.49B | $8.51B |
PGNY vs CI vs UNH vs ELV vs CVS — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | May 20 | May 26 | Return |
|---|---|---|---|
| Progyny, Inc. (PGNY) | 100 | 95.0 | -5.0% |
| Cigna Corporation (CI) | 100 | 146.0 | +46.0% |
| UnitedHealth Group … (UNH) | 100 | 124.6 | +24.6% |
| Elevance Health Inc. (ELV) | 100 | 128.5 | +28.5% |
| CVS Health Corporat… (CVS) | 100 | 138.1 | +38.1% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PGNY vs CI vs UNH vs ELV vs CVS
Each card shows where this stock fits in a portfolio — not just who wins on paper.
PGNY is the #2 pick in this set and the best alternative if quality and efficiency is your priority.
- 5.2% margin vs CVS's 0.7%
- 9.0% ROA vs CVS's 1.1%, ROIC 18.1% vs 5.0%
CI ranks third and is worth considering specifically for growth exposure and sleep-well-at-night.
- Rev growth 11.3%, EPS growth 82.9%, 3Y rev CAGR 15.1%
- Lower volatility, beta 0.38, Low D/E 75.1%, current ratio 0.85x
- Lower P/E (9.5x vs 20.7x)
UNH is the clearest fit if your priority is long-term compounding.
- 228.3% 10Y total return vs ELV's 205.8%
ELV is the clearest fit if your priority is valuation efficiency.
- PEG 2.04 vs PGNY's 2.99
- 12.6% revenue growth vs CVS's 7.8%
CVS carries the broadest edge in this set and is the clearest fit for income & stability and defensive.
- Dividend streak 0 yrs, beta 0.13, yield 3.0%
- Beta 0.13, yield 3.0%, current ratio 0.84x
- Beta 0.13 vs PGNY's 0.79
- 3.0% yield, vs UNH's 2.3%, (1 stock pays no dividend)
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 12.6% revenue growth vs CVS's 7.8% | |
| Value | Lower P/E (9.5x vs 20.7x) | |
| Quality / Margins | 5.2% margin vs CVS's 0.7% | |
| Stability / Safety | Beta 0.13 vs PGNY's 0.79 | |
| Dividends | 3.0% yield, vs UNH's 2.3%, (1 stock pays no dividend) | |
| Momentum (1Y) | +37.4% vs CI's -11.7% | |
| Efficiency (ROA) | 9.0% ROA vs CVS's 1.1%, ROIC 18.1% vs 5.0% |
PGNY vs CI vs UNH vs ELV vs CVS — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
PGNY vs CI vs UNH vs ELV vs CVS — Financial Metrics
Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
PGNY leads in 2 of 6 categories
CVS leads 2 • CI leads 1 • UNH leads 0 • ELV leads 0 • 1 tied
Explore the data ↓Income & Cash Flow (Last 12 Months)
PGNY leads this category, winning 5 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
UNH is the larger business by revenue, generating $449.7B annually — 347.8x PGNY's $1.3B. Profitability is closely matched — net margins range from 5.2% (PGNY) to 0.7% (CVS). On growth, CVS holds the edge at +6.2% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||
|---|---|---|---|---|---|
| RevenueTrailing 12 months | $1.3B | $277.9B | $449.7B | $200.4B | $407.9B |
| EBITDAEarnings before interest/tax | $100M | $12.1B | $23.2B | $8.9B | $10.5B |
| Net IncomeAfter-tax profit | $68M | $6.3B | $12.0B | $5.2B | $2.9B |
| Free Cash FlowCash after capex | $181M | $7.7B | $19.7B | $6.5B | $7.4B |
| Gross MarginGross profit ÷ Revenue | +24.1% | +9.3% | +18.8% | +23.2% | +13.9% |
| Operating MarginEBIT ÷ Revenue | +7.5% | +3.4% | +4.2% | +3.8% | +1.5% |
| Net MarginNet income ÷ Revenue | +5.2% | +2.3% | +2.7% | +2.6% | +0.7% |
| FCF MarginFCF ÷ Revenue | +14.0% | +2.8% | +4.4% | +3.2% | +1.8% |
| Rev. Growth (YoY)Latest quarter vs prior year | +1.4% | +4.6% | +2.0% | +2.6% | +6.2% |
| EPS Growth (YoY)Latest quarter vs prior year | +70.6% | +29.1% | +0.7% | -16.8% | +63.1% |
Valuation Metrics
CI leads this category, winning 5 of 7 comparable metrics.
Valuation Metrics
At 13.0x trailing earnings, CI trades at a 80% valuation discount to CVS's 65.1x P/E. Adjusting for growth (PEG ratio), ELV offers better value at 2.18x vs PGNY's 5.45x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||
|---|---|---|---|---|---|
| Market CapShares × price | $1.9B | $76.0B | $344.9B | $82.1B | $115.5B |
| Enterprise ValueMkt cap + debt − cash | $1.9B | $99.7B | $398.9B | $105.8B | $200.6B |
| Trailing P/EPrice ÷ TTM EPS | 36.49x | 12.99x | 28.72x | 15.05x | 65.14x |
| Forward P/EPrice ÷ next-FY EPS est. | 20.00x | 9.48x | 20.71x | 14.11x | 12.39x |
| PEG RatioP/E ÷ EPS growth rate | 5.45x | — | — | 2.18x | — |
| EV / EBITDAEnterprise value multiple | 20.55x | 8.48x | 17.10x | 10.96x | 13.38x |
| Price / SalesMarket cap ÷ Revenue | 1.51x | 0.28x | 0.77x | 0.41x | 0.29x |
| Price / BookPrice ÷ Book value/share | 4.11x | 1.83x | 3.40x | 1.90x | 1.53x |
| Price / FCFMarket cap ÷ FCF | 10.13x | 9.05x | 21.46x | 25.87x | 14.80x |
Profitability & Efficiency
PGNY leads this category, winning 6 of 9 comparable metrics.
Profitability & Efficiency
CI delivers a 15.1% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $4 for CVS. PGNY carries lower financial leverage with a 0.05x debt-to-equity ratio, signaling a more conservative balance sheet compared to CVS's 1.24x. On the Piotroski fundamental quality scale (0–9), CI scores 8/9 vs CVS's 5/9, reflecting strong financial health.
| Metric | |||||
|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +13.3% | +15.1% | +11.5% | +11.9% | +3.9% |
| ROA (TTM)Return on assets | +9.0% | +4.1% | +3.9% | +4.3% | +1.1% |
| ROICReturn on invested capital | +18.1% | +10.4% | +9.2% | +9.1% | +5.0% |
| ROCEReturn on capital employed | +17.4% | +9.2% | +9.7% | +8.2% | +6.1% |
| Piotroski ScoreFundamental quality 0–9 | 6 | 8 | 6 | 6 | 5 |
| Debt / EquityFinancial leverage | 0.05x | 0.75x | 0.77x | 0.75x | 1.24x |
| Net DebtTotal debt minus cash | -$88M | $23.8B | $54.0B | $23.7B | $85.1B |
| Cash & Equiv.Liquid assets | $112M | $7.7B | $24.4B | $9.5B | $8.5B |
| Total DebtShort + long-term debt | $24M | $31.5B | $78.4B | $33.2B | $93.6B |
| Interest CoverageEBIT ÷ Interest expense | — | 6.77x | 4.71x | 5.39x | 2.11x |
Total Returns (Dividends Reinvested)
CVS leads this category, winning 5 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in CVS five years ago would be worth $11,977 today (with dividends reinvested), compared to $4,656 for PGNY. Over the past 12 months, CVS leads with a +37.4% total return vs CI's -11.7%. The 3-year compound annual growth rate (CAGR) favors CVS at 12.2% vs PGNY's -12.0% — a key indicator of consistent wealth creation.
| Metric | |||||
|---|---|---|---|---|---|
| YTD ReturnYear-to-date | -7.8% | +3.8% | +13.6% | +7.2% | +14.7% |
| 1-Year ReturnPast 12 months | +1.5% | -11.7% | +0.8% | -6.7% | +37.4% |
| 3-Year ReturnCumulative with dividends | -31.9% | +15.2% | -17.8% | -14.5% | +41.2% |
| 5-Year ReturnCumulative with dividends | -53.4% | +17.5% | -0.9% | +1.4% | +19.8% |
| 10-Year ReturnCumulative with dividends | +48.8% | +139.6% | +228.3% | +205.8% | +6.6% |
| CAGR (3Y)Annualised 3-year return | -12.0% | +4.8% | -6.3% | -5.1% | +12.2% |
Risk & Volatility
CVS leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
CVS is the less volatile stock with a 0.13 beta — it tends to amplify market swings less than PGNY's 0.79 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CVS currently trades 99.6% from its 52-week high vs PGNY's 82.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||
|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 0.79x | 0.38x | 0.60x | 0.48x | 0.13x |
| 52-Week HighHighest price in past year | $28.75 | $338.89 | $390.92 | $424.24 | $90.88 |
| 52-Week LowLowest price in past year | $16.10 | $239.51 | $234.60 | $273.71 | $58.35 |
| % of 52W HighCurrent price vs 52-week peak | +82.5% | +85.0% | +97.2% | +89.1% | +99.6% |
| RSI (14)Momentum oscillator 0–100 | 62.8 | 55.1 | 76.9 | 73.5 | 70.0 |
| Avg Volume (50D)Average daily shares traded | 1.5M | 1.6M | 7.9M | 1.8M | 7.5M |
Analyst Outlook
Evenly matched — UNH and CVS each lead in 1 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: PGNY as "Buy", CI as "Buy", UNH as "Buy", ELV as "Buy", CVS as "Buy". Consensus price targets imply 29.8% upside for PGNY (target: $31) vs 1.1% for ELV (target: $382). For income investors, CVS offers the higher dividend yield at 2.95% vs ELV's 1.82%.
| Metric | |||||
|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy | Buy | Buy | Buy |
| Price TargetConsensus 12-month target | $30.80 | $336.18 | $385.43 | $382.38 | $96.75 |
| # AnalystsCovering analysts | 20 | 39 | 52 | 37 | 41 |
| Dividend YieldAnnual dividend ÷ price | — | +2.1% | +2.3% | +1.8% | +3.0% |
| Dividend StreakConsecutive years of raises | — | 6 | 25 | 15 | 0 |
| Dividend / ShareAnnual DPS | — | $6.06 | $8.70 | $6.89 | $2.67 |
| Buyback YieldShare repurchases ÷ mkt cap | +4.2% | +4.8% | +1.6% | +3.2% | 0.0% |
PGNY leads in 2 of 6 categories (Income & Cash Flow, Profitability & Efficiency). CVS leads in 2 (Total Returns, Risk & Volatility). 1 tied.
PGNY vs CI vs UNH vs ELV vs CVS: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is PGNY or CI or UNH or ELV or CVS a better buy right now?
For growth investors, Elevance Health Inc.
(ELV) is the stronger pick with 12. 6% revenue growth year-over-year, versus 7. 8% for CVS Health Corporation (CVS). Cigna Corporation (CI) offers the better valuation at 13. 0x trailing P/E (9. 5x forward), making it the more compelling value choice. Analysts rate Progyny, Inc. (PGNY) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — PGNY or CI or UNH or ELV or CVS?
On trailing P/E, Cigna Corporation (CI) is the cheapest at 13.
0x versus CVS Health Corporation at 65. 1x. On forward P/E, Cigna Corporation is actually cheaper at 9. 5x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Elevance Health Inc. wins at 2. 04x versus Progyny, Inc. 's 2. 99x.
03Which is the better long-term investment — PGNY or CI or UNH or ELV or CVS?
Over the past 5 years, CVS Health Corporation (CVS) delivered a total return of +19.
8%, compared to -53. 4% for Progyny, Inc. (PGNY). Over 10 years, the gap is even starker: UNH returned +228. 3% versus CVS's +6. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — PGNY or CI or UNH or ELV or CVS?
By beta (market sensitivity over 5 years), CVS Health Corporation (CVS) is the lower-risk stock at 0.
13β versus Progyny, Inc. 's 0. 79β — meaning PGNY is approximately 506% more volatile than CVS relative to the S&P 500. On balance sheet safety, Progyny, Inc. (PGNY) carries a lower debt/equity ratio of 5% versus 124% for CVS Health Corporation — giving it more financial flexibility in a downturn.
05Which is growing faster — PGNY or CI or UNH or ELV or CVS?
By revenue growth (latest reported year), Elevance Health Inc.
(ELV) is pulling ahead at 12. 6% versus 7. 8% for CVS Health Corporation (CVS). On earnings-per-share growth, the picture is similar: Cigna Corporation grew EPS 82. 9% year-over-year, compared to -62. 0% for CVS Health Corporation. Over a 3-year CAGR, PGNY leads at 17. 9% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — PGNY or CI or UNH or ELV or CVS?
Progyny, Inc.
(PGNY) is the more profitable company, earning 4. 5% net margin versus 0. 4% for CVS Health Corporation — meaning it keeps 4. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PGNY leads at 6. 6% versus 2. 6% for CVS. At the gross margin level — before operating expenses — ELV leads at 25. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is PGNY or CI or UNH or ELV or CVS more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, Elevance Health Inc. (ELV) is the more undervalued stock at a PEG of 2. 04x versus Progyny, Inc. 's 2. 99x. Both stocks trade at elevated growth-adjusted valuations, so expected growth needs to materialise. On forward earnings alone, Cigna Corporation (CI) trades at 9. 5x forward P/E versus 20. 7x for UnitedHealth Group Incorporated — 11. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PGNY: 29. 8% to $30. 80.
08Which pays a better dividend — PGNY or CI or UNH or ELV or CVS?
In this comparison, CVS (3.
0% yield), UNH (2. 3% yield), CI (2. 1% yield), ELV (1. 8% yield) pay a dividend. PGNY does not pay a meaningful dividend and should not be held primarily for income.
09Is PGNY or CI or UNH or ELV or CVS better for a retirement portfolio?
For long-horizon retirement investors, CVS Health Corporation (CVS) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.
13), 3. 0% yield). Both have compounded well over 10 years (CVS: +6. 6%, PGNY: +48. 8%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between PGNY and CI and UNH and ELV and CVS?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: PGNY is a small-cap quality compounder stock; CI is a mid-cap deep-value stock; UNH is a large-cap quality compounder stock; ELV is a mid-cap deep-value stock; CVS is a mid-cap quality compounder stock. CI, UNH, ELV, CVS pay a dividend while PGNY does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.